Speakers
Nicholas Agard, Scientist, Genentech
Methal Albarghouthi, Director, Analytical Sciences, AstraZeneca
Omar Ali, Visiting Lecturer, University of Portsmouth
Philip Arlen, President And Chief Executive Officer, Precision Biologics Inc
Tudor Arvinte, President And Chief Executive Officer, Therapeomic Inc
Rene Assenberg, Associate Director, Janssen Pharmaceutical
Sameer Awsare, Associate Executive Director, The Permanente Medical Group Inc
Jessica Baker Flechtner, Chief Scientific Officer, Genocea Biosciences
Caroline Barelle, Chief Executive Officer, Elasmogen
Hanmant Barkate, Senior Vice President, Global Medical Affairs, Glenmark Pharmaceuticals SA
dorthe bartels, negotiator, amgros
Amrik Basran, Chief Scientific Officer, Avacta Life Sciences
Alexander Baumann, Head Technical Support Europe, Europhins Pharma Discovery Services
Roy Baynes, Senior Vice President And Head Global Clinical Development, Chief Medical Officer, Merck Research Laboratories
Alain Beck, Senior Director, Centre d'Immunologie Pierre Fabre
Philip Beer, Physician Scientist And Precision Oncology Specialist, Sanger Institute
Stephen Beers, Associate Professor, university of Southampton
Jannick Bendtsen, CEO, PipeBio ApS
Martin Bertschinger, Deputy Cell Sciences Director, Ichnos Sciences
María Lucía Bettati, Business Unit Director Gen Med, Amgen
mr Florian Bieber, Vice President Of Clinical Development And Drug Safety, Sandoz
Horst Bierau, Senior Scientific Advisor - Head CMC Science & Intelligence, Merck Serono
Jennifer Bolsee, Research & Development Associate, Celyad Oncology
Ezio Bonvini, Chief Scientific Officer, MacroGenics
Ailsa Bosworth, National Patient Champion, National Rheumatoid Arthritis Society
Carlo Boutton, Global Head Innovation, Large Molecule Research Platform, sanofi
Emmanuel Briend, Associate Antibody Discovery Director, Agenus
Kate Broderick, Senior Vice President, Research And Development, Inovio Pharmaceuticals
Kathryn Brown, Intermin Vice President for pharmacy, Kaiser Permanente
Patrick Bulau, Senior Principal Scientist, Roche Pharma
Sebastian Bunk, Senior Director, Pipeline Research, Immatics Biotechnologies GmbH
Ping Cao, VP, Business Development, Shanghai Henlius Biotech, Inc
Antonella Cardone, Director, European Cancer Patient Coalition
Sara Carillo, Applications Development Team Leader, NIBRT
Samuele Cazzamalli, Group Head, Philochem
Victor Cervera-Carrascon, Head Of Immunology, TILT Biotherapeutics
Brian Champion, CSO, PsiOxus Therapeutics Ltd
eleni chantzoura, Associate Director, AgenTus Therapeutics
John Chappell, Application And Service Director Emea And Asia Pacific, Gyros Protein Technologies
Maggie Cheang, Team Leader, Genomic Analysis – Clinical Trials, Institute of Cancer Research
Vijay Chudasama, Reader, UCL
Eduardo Cioppi, Quality Operations and Regulatory Affairs Manager, Amega Biotech
Eduardo Cioppi, Global Market Access & Public Affairs Director, mAbxience Research S.L.
Sara Colombetti, Global Head Oncology Discovery Pharmacology, Roche Innovation Center Zurich
James Crowe, Director, Vanderbilt Vaccine Center
Marcin Czech, Professor, Institute Of Mother And Child
Blake Dark, Commercial Medicines Director, NHS England
Roberto De Luca, Senior Scientist, Philochem AG
Johan De Munter, Executive Board Member, European Oncology Nursing Society
Annick De Vries, Head Diagnostics, Biologics, Sanquin
John Delaney, Director, Research Technologies And Collaborations, Amgen Inc
Mahendra Deonarain, CEO, Antikor
Audrey Desgranges, Business Developer, McSAF
David Di Lillo, Associate Director, Regeneron
Gundo Diedrich, Senior Director, MacroGenics
Dimiter Dimitrov, Professor Of Medicine, University of Pittsburgh
Jean-Cosme Dodart, SVP of Preclinical R&D at Vaxxinity, Vaxxinity
Achim Doerner, Principal Scientist, Merck KGaA
Helena Domingues, Patent Examiner, European Patent Office
Ramana Doppalapudi, Director Of Chemistry, Avidity BioSciences
Roman Drai, RnD Director, GEROPHARM
Alix Dubes, Senior Director Patent Attorney, Biosimilars at Fresenius Kabi, Fresenius Kabi
Stefan Duebel, Director, Technical University of Braunschweig
Robert Duncombe, Medical Director, The Christie N.H.S. Foundation Trust
Lindy Durrant, Professor Of Cancer Immunotherapy, University Of Nottingham
Pascal Egloff, Platform Leader, University of Zurich
Geoffrey Esteban, General Manager, IPRASENSE
David Falck, Assistant Professor, Leiden University Medical Center (Netherlands)
MOURAD FERHAT, Product Manager, IsoPlexis
Maria Fiammetta Romano, Prof, University of Naples Federico II
Kalveer Flora, Lead Rheumatology And Biosimilars Specialist Pharmacist, London North West University Healthcare NHS Trust
Richard Frank, Health Economics Professor, Harvard University
Federica Fraschetti, Associate Director, MSD, Merck
Bjorn Frendeus, Chief Scientific Officer, BioInvent
Thomas Fryer, Industrial Postdoc, Technical University of Denmark
Hanspeter Gerber, CSO, 3T Biosciences
Bruno Gomes, Global Head Of Biomarkers Oncology, Roche
Deya Gonzalez, Prof, Swansea University
Andrew Goodearl, Director, Abbvie
Anne Goubier, Vice President Of Immunology, Tusk Therapeutics
Victor Greiff, Associate Professor, Department Of Immunology, The University of Oslo
Farshad Guirakhoo, CSO, Vaxxinity
Tea Gunde, Chief Research Officer, Numab Therapeutics AG
Thomas Hach, Executive Director, Patient Engagement Cardiovascular, Renal & Metabolism, Novartis
Eric Halioua, President & CEO, PDC*line pharma SA
Jenny Hao, Managing Director, Access Now
Eliott Harfouche, Partner, Nodes Advisors
Katherine Harris, VP Discovery, Teneobio
Kristen Hege, Senior Vice President, Early Clinical Development, Hematology/Oncology and Cell Therapy, Bristol-Myers Squibb
Ana Hidalgo-Simon, Head of Advanced Therapies, European Medicines Agency
Lawrence Hill, Chief Executive Officer, Gan & Lee Pharmaceuticals USA
Oliver Hill, Vice President, Drug Discovery, Protein Engineering, Apogenix AG
Soraya Hölper, Lab Head Mass Spectrometry, Sanofi - Biologics Research
Thomas Huber, Research director, Almirall
Alissa Hummer, DPhil Student, University of Oxford
Sophia Humphreys, Director, System Pharmacy Clinical Services, Providence Health System
Gregor Hutter, Research Group Leader, University Hospital Basel
Ylenia Ingrasciotta, Senior Pharmacoepidemiologist, University of Messina
Melita Irving, Group Leader T-Cell Engineering, University of Lausanne
Vibha Jawa, Executive Director, BMS
Timothy Jenkins, H.C. Orsted Postdoctoral Fellow, Technical University of Denmark
Colette Johnston, Senior Director, Early Discovery, Crescendo Biologics Ltd
Peter Jorgensen, Chief Executive Officer, Danish Generic and Biosimilar Medicines Industry Association (IGL)
Jennifer Jung, Lab Head Mass Spectrometry, sanofi
Hye Na Kang, Scientist, WHO
Sophia Karagiannis, Professor Of Translational Cancer Immunology And Immunotherapy, King's College London
Hans S Keirstead, Chief Executive Officer, AIVITA Biomedical, Inc.
Sridevi Khambhampaty, Vice President Biosimilar Product Development And Regulatory Affairs, Intas Pharmaceuticals Ltd
Mohamed Khater, Samsung Bioepis
Dr Christian Klein, Dept Head, Roche Pharmaceutical Research and Early Development
Eva Kollar, Team Lead, Formulation Development, Biotechnology, Gedeon Richter PLC
Harald Kolmar, Head of department applied biochemistry, TU Darmstadt Biochemie
Jiri Kovarik, Research Investigator, NIBR
Dan Bach Kristensen, Principal Scientist, Symphogen
Hannah Kuchler, US Pharma and Biotech Correspondent, Financial Times
Russell Lamontagne, Chief Executive Officer, Boston Immune Technologies And Therapeutics
David Lancaster, Partner, Pinsent Masons LLP
Heinz Läubli, Attending Physician, Medical Oncology, University Hospital Basel
Andreas Hougaard Laustsen, Postdoctoral, Technical University of Denmark
Christophe Le Tourneau, Head Of Clinical Research, Department Of Medical Oncology, Curie Institute
Line Ledsgaard, PhD student, Technical University of Denmark
Steve Lehrer, Managing Director, SBLehrer LLC
Jeanette Leusen, Associate Professor, Laboratory, Translational Immunology, UMC Utrecht
Mark Levick, Chief Executive Officer, Alvotech
Stephen Lock, Marketing and Business development Manager, EMEAI, Sciex
John Lofblom, Professor in Combinatorial Protein Engineering, K.T.H. Royal Institute of Technology
Angelica Loskog, Chief Executive Officer, Lokon Pharma
Peter Lowe, Director, Biologics Generation And Optimization, Pierre Fabre
Heinz Lubenau, Chief Executive Officer, Vaximm Gmbh
Nanna Luneborg, Partner, Novo Ventures
Geoffrey Lynn, Chief Executive Officer and Co-Founder, Avidea Technologies
Nicolas Mach, Head of Clinical Research Unit, MaxiVAX
Harbani Malik, Sr Scientist Protein Sciences, Teneobio
Bernard Malliere, Head of laboratory, CEA
Erik Manting, CEO, Immunicum
Julie Marechal-Jamil, Biosimilars Policy & Science, Medicines for Europe
Andrea Marschall, Postdoctoral, Brandeis University
Shyam Masrani, Principal, Medicxi
Nena Matscheko, Senior Scientist, Dynamic Biosensors
Lamine Mbow, Chief Scientific Officer, Ichnos Sciences
Joseph McClellan, Chief Scientific Officer, Alvotech
Stewart Mcnaull, Senior VP, Business Development, KBI Biopharma
Christoph Merten, Professor, Laboratory for Biomedical Microfluidics, EPFL
Chad Mitchell, Manager - Pharmaceuticals, Alberta Health Services
Ali Mohamed, Vice President, CMC, Immatics Inc
Prem Mohanty, Product Marketing Manager, Benchling
Dario Neri, Co-Founder, Philogen; Department Of Chemistry And Applied Biosciences, Swiss Federal Institute of Technology Zurich
Sarfaraz Niazi, Professor, University of Illinois
Cecil Nick, Vice President - Technical, Parexel
Johan Nilvebrant, Researcher, K.T.H. Royal Institute of Technology
Ahuva Nissim, Professor, William Harvey Research Institute
Maximilian Nitschke, Principal Scientific Researcher, Genentech
Oliver Nussbaumer, VP, Immunology, GammaDelta Therapeutics
David O'Connell, Assistant Professor, School Of Biomolecular And Biomedical Science, University College Dublin
Benjamí Oller-Salvia, Assistant Professor, Ramon Llull University (URL)
Ber Oomen, Executive Secretary And Treasurer, European Specialist Nurses Organisations
Madan Paidhungat, Director, Protein Engineering, Cytom X Therapeutics
Marc Pallardy, Professor and head of the Department of Toxicology, Universite Paris Sud
Rajita Pappu, Senior Scientist, Genentech
Paul Parren, EVP, Lava Therapeutics
Lauri Peil, Key Account And Technology Officer, Icosagen Cell Factory OU
Martin Perry, Consultant Physician And Rheumatologist, Honorary Senior Clinical Lecturer, NHS Greater Glasgow & Clyde
Sari Pesonen, Head Of R&D, Co-Founder, Valo Therapeutics
Jutta Petschenka, Principal Scientist, Boehringer Ingelheim
Tanja Piller, Analytics Expert, Sanofi
Thomas Pillow, Senior Scientist, Genentech
Samuel Pine, Head of Bioanalysis and Immunogenicity, Ablynx, a Sanofi company
Adam Platt, Global Head Of Genomics Portfolio, Head Of The Ria Companion Diagnostic Unit (Ria Cdu) In Personalised Healthcare And Biomarkers, AstraZeneca
Andreas Plueckthun, Professor Of Biochemistry, Director, Department Of Biochemistry, University of Zurich
Christopher Plummer, Antibody Selections Team Leader, GSK
Ned Pojskic, Leader, Pharmacy And Health Provider Relations, Greenshield Insurance Brokers LLC
Elke Prade, Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
Christophe Queva, Chief Scientific Officer, Oncorus
Alfonso Quintas, Chief Medical Officer, TCR2 Therapeutics
Eva Rahman Kabir, Professor, Brac University
Sundar Ramanan, Vice President, Head, Global Regulatory Affairs, Biocon Pharmaceuticals
Matthew Raybould, Postdoctoral Researcher, University of Oxford
Isabell Remus, Head Biosimilars & Specialty Business, Europe, Sandoz
Nina Reschke, Senior Scientist Immuno-Oncology Research, Group Leader, Molecular Partners AG
Brent Rice, Vice President, Global Market Access, Autolus
Nicoló Rigamonti, Project Leader And Biology Lead, Molecular Partners AG
Udo Roth, Laboratory Head MS, Sanofi Pasteur
Mark Samaan, Consultant Gastroenterologist, Guy’s and St Thomas N.H.S Foundation Trust
Mark Samuels, Chief Executive Ofiicer, British Generic Manufacturers Association (BGMA)
Aaron Sato, Chief Scientific Officer of Twist Biopharma, Twist Bioscience
Karsten Sauer, VP, Repertoire Immune Medicines
Martin Schiestl, Chief Science Officer, Sandoz (Novartis)
Thomas Schirrmann, CEO & Founder, CORAT Therapeutics
Karoline Schjetne, Vice President, Head of Bioanalytical Sciences, Vaccibody As
Sebastian Schlicker, Director Biologics, Genedata AG
Philip Schneider, Advisory Board Chair, Alliance for Safe Biologic Medicines
Maren Schubert, Postdoc, Technical University of Braunschweig
Ed Schuuring, head lab of Molecular Pathology, University of Groningen
Chris Scott, Acting Director of the Patrick Johnston Centre for Cancer Research, Queen's University Belfast
Markus Seeger, Associate Professor, University of Zurich
Peter Senter, Vice President Of Chemistry, Seattle Genetics Inc
Armin Sepp, Scientific Leader And Gsk Associate Fellow, GlaxSmithKline
Limin Shang, Director Of Pharmacology, Light Chain Bioscience - A brand of Novimmune SA
Tim Shea, Director, Sterne Kessler Goldstein And Fox Plc
Arne Skerra, Professor - Biological Chemistry, TU Munich
Alessandro Slama, General Manager and Senior Director EMEA at US Pharmacopeia, US Pharmacopoeia
Meaghan Smith, Executive Director, The Biosimilars Forum
Andreu Soldevila, Chief Executive Officer, Syna Therapeutics
Pietro Sormanni, Group Leader, University of Cambridge
Andrew Spiegel, Executive Director, Globol Colon Cancer Association
David Spring, Professor, University of Cambridge
Philipp Spycher, Psi Founder Fellow, Paul Scherrer Institut
Blaine Stine, Director, Global Biologics Discovery, Abbvie
Pawel Stocki, Reseach Director, Ossianix, Inc.
Lars Stockl, Division Manager, FyoniBio – Service Branch of Glycotope
Peter Szijj, Phd Student, University College London
Bert Thomas, Senior Vice President Of Business Development, Bio-Thera Solutions
Steve Thorne, Chief Scientific Officer, Western Oncolytics
Greg Thurber, Assistant Professor Of Chemical Engineering, University of Michigan
matthew turner, Head government affairs Europe, ROW, Fresenius Kabi
Mart Ustav, CSO, Icosagen Cell Factory OU
Omid Vafa, Chief Business Officer, Teneobio
Timo van den Berg, Professor and group leader, Sanquin Research
Hans Van Der Vliet, Chief Scientific Officer And Senior Vice President, Lava Therapeutics
Marjolein Van Egmond, Professor Of Oncology And Inflammation, VU University Medical Center Amsterdam
Marit van Gils, Associate Professor, Amsterdam UMC
Bernard Vanhove, COO, Xenothera
Alain VERTES, Managing Director, NxR Biotechnologies
Eric Vivier, Senior Vice President And Chief Scientific Officer, Innate Pharma
Johannes Vom Berg, Groupleader, University of Zurich
Meenu Wadhwa, Section Leader For Cyotkines And Growth Factors Section, NIBSC
Alain Wagner, Research Director, Centre National De La Recherche Scientifique
Sally Ward, Professor of Molecular Immunology and Director of Translational Immunology, University of Southampton
Christopher Webster, Principal, BioApprovals
Michael Wiechmann, Global Head Of Medical Affairs Biopharmaceuticals And Biosimilars, Sandoz
Yariv Wine, Senior Lecturer And Assistant Professor, Tel Aviv University
Markus Zettl, Director Immuno, Oncology, Pieris Pharmaceuticals
Jing Zhao, CBO, Refuge Biotechnologies
Stefan Zielonka, Associate Director, Protein Engineering And Antibody Technologies, Merck KGaA
SOCIAL MEDIA
GET INVOLVED
For speaking, sponsorship or exhibition opportunities, please contact:
Derek Cavanagh, Tel: +44 (0)207 092 1297, derek.cavanagh@terrapinn.com
Organiser
